Envoy Medical, Inc.: Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.
How this was made
The 30-second read
Why it matters
The new 12-month Stage 1 data show continued CNC word recognition improvement versus baseline and versus the prior 6-month mean, with no protocol-defined serious adverse events reported through 12 months. This strengthens the narrative that the primary endpoint will be met on 12-month data, while Stage 2 is already enrolled and progressing toward a full 12-month dataset for the PMA submission.
Market read
Traders may reprice COCH’s clinical-risk profile based on the updated 12-month efficacy trajectory and safety update, while awaiting broader endpoint data and Stage 2 completion.
What to watch
The article does not provide AzBio, quality-of-life, or other endpoints in this top-line release, and it does not quantify statistical significance or variability; FDA review outcomes remain uncertain.
Background
Envoy Medical is running a two-stage pivotal clinical trial for its investigational fully implanted Acclaim cochlear implant, with Stage 1 interim data previously reported at 6 months.
Ticker impact
Envoy Medical reported 12-month Stage 1 pivotal trial data for its Acclaim fully implanted cochlear implant, with mean CNC improving to 53.2% from 15.2%.
Likely near-term positive bias for COCH on clinical-data sentiment, though magnitude may be tempered by small Stage 1 sample size and interim nature.
The article discloses new, time-specific clinical datapoints (12-month CNC, responder/non-responder detail, and SAE absence) and reiterates that primary endpoint assessment is on 12-month data, but it is still interim and limited to the first 10 participants in Stage 1.
Market effects
Supports sentiment for fully implanted hearing device platforms and may increase investor appetite for adjacent medtech with similar FDA pathways.
No specific regional macro linkage; impact is primarily company-specific within US small/mid-cap medtech.
Primarily US regulatory and clinical-trial driven; could influence global investor perception of cochlear implant innovation timelines.
Counterpoint
The readout is interim and based on only 10 Stage 1 participants, including one potential non-responder, so the market may discount durability and generalizability.
Key entities
- companyEnvoy Medical, Inc.
NASDAQ-listed hearing health company reporting 12-month Stage 1 pivotal trial data for its Acclaim fully implanted cochlear implant.
- productAcclaim cochlear implant
Investigational fully implanted cochlear implant in Envoy’s two-stage pivotal clinical trial; primary efficacy endpoint assessed on 12-month data.
- regulatorFDA
US regulator for the PMA submission; Breakthrough Device Designation noted and pivotal trial milestones referenced.
